Lifecare ASA

Share Issue/Capital Change • Dec 30, 2025

Lifecare ASA: Updated key information relating to the proposed partially underwritten rights issue

Lifecare ASA: Updated key information relating to the proposed partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED

STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE

PEOPLE'S REPUBLIC OF CHINA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement by Lifecare ASA

("Lifecare" or the "Company") on 22 October 2025 with preliminary key

information relating to the proposed partially underwritten rights issue of

new shares in the Company (the "Offer Shares") with preferential subscription

rights for existing shareholders (the "Subscription Rights"), raising gross

proceeds of minimum NOK 80 million and up to NOK 100 million (the "Rights

Issue"). The proposed subscription price per Offer Share has now been set, and

updated key information relating to the Rights Issue is included below.

Date on which the terms and conditions of the Rights Issue were announced: 22

October 2025

Last day including right: 2 January 2026

Ex-date: 5 January 2026

Record Date: 6 January 2026

Date of approval: 2 January 2026 (extraordinary general meeting)

Maximum number of Offer Shares: 200,000,000

Subscription price: NOK 0.50 per Offer Share

Ratio Subscription Rights: 10.49 Subscription Rights per share held as of the

Record Date

Subscription ratio: One Subscription Right gives the right to subscribe for

one Offer Share

Managers: DNB Carnegie, a part of DNB Bank ASA, and SB1 Markets AS

Will the Subscription Rights be listed: The Company will apply for trading of

the Subscription Rights on Euronext Oslo Børs

ISIN for the Subscription Rights: NO0013699884

Other information: The proposed subscription price of NOK 0.50 per Offer Share

has been set based on the theoretical share price exclusive of the

Subscription Rights (TERP) based on the volume-weighted average price (VWAP)

of the Company's shares on Euronext Oslo Børs the three trading days prior to

the date of the extraordinary general meeting for approval of the Rights Issue

to be held on 2 January 2026 (the "Rights Issue EGM"), less a discount of 35%.

The Rights Issue is subject to approval by the Rights Issue EGM.

Subscribers in the Rights Issue will, without cost, receive warrants (Nw.

frittstående tegningsretter) in two series (a) three (3) warrants for every

four (4) Offer Shares allocated to, and paid by, them in the Rights Issue,

which will be exercisable in the exercise period from 2 March 2026 to 13 March

2026 ("Warrants Series 1"); and (b) three (3) warrants for every four (4)

Offer Shares allocated to, and paid by them, in the Rights Issue, which will

be exercisable in the exercise period from 1 June 2026 to 12 June 2026

("Warrants Series 2" and together with Warrants Series 1, the "Warrants").

Each Warrant will give the holder a right to subscribe for one (1) new share

in the Company at a subscription price equal to 70% of the volume-weighted

average price (VWAP) of the Company's shares on Euronext Oslo Børs on the last

ten (10) trading days prior to the first date on which the holder can exercise

the Warrant in the relevant exercise period, but in any event not exceeding

NOK 0.625 (the subscription price in the Rights Issue plus 25%). The

subscription price may not be lower than the par value of the Company's

shares.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication, through the

agency of the contact persons set out above, at 2025-12-30 19:05 CET.